

**DRUG NAME: Pamidronate****SYNONYM(S):** Pamidronate disodium, pamidronic acid, APD, aminohydroxypropylidene bisphosphonate**COMMON TRADE NAME(S):** AREDIA®**CLASSIFICATION:** Bone metabolism regulator**MECHANISM OF ACTION:**

Pamidronate is a second-generation bisphosphonate, which inhibits bone resorption.<sup>1</sup> Bisphosphonates are analogues of endogenous pyrophosphate and characterized by a P-C-P bond, which is resistant to enzymatic hydrolysis.<sup>2</sup> The mechanism of action of bisphosphonates has not been fully elucidated. Available data suggests that they bind strongly to hydroxyapatite crystals in the bone matrix, preferentially at the sites of increased bone turnover and inhibit the formation and dissolution of the crystals. Other actions of matrix-bound bisphosphonates may include direct inhibition of mature osteoclast function, promotion of osteoclast apoptosis and interference with osteoblast-mediated osteoclast activation.<sup>3</sup> Pamidronate does not interfere with bone mineralization at therapeutic doses.<sup>1</sup> On a molar basis, pamidronate is 10 times more potent than clodronate.<sup>2</sup> In tumour-induced hypercalcemia, bone resorption is increased in the presence of neoplastic tissue. Pamidronate inhibits abnormal bone resorption and reduces the flow of calcium from the resorbing bone into the blood, thus, decreasing total and ionized serum calcium. In the treatment of osteolytic bone metastases in breast cancer and multiple myeloma, pamidronate helps reducing morbidity of bone metastases by inhibiting accelerated bone resorption induced by the tumour.<sup>4</sup>

**PHARMACOKINETICS:**

Interpatient variability	no information found	
Oral Absorption	<1% absorbed <sup>5</sup>	
Distribution	45-53% is adsorbed to bone in the areas of high turnover after an intravenous dose of 60 mg infused over 24 hours. <sup>4</sup> Body retention of pamidronate correlates with the number of bone metastases in patients with cancer. <sup>3</sup>	
	cross blood brain barrier?	no information found
	volume of distribution	no information found
	plasma protein binding	54% <sup>4</sup>
Metabolism	does not appear to be metabolized	
	active metabolite(s)	none
	inactive metabolite(s)	none
Excretion	renal excretion; there is a tendency for renal clearance to correlate with creatinine clearance.	
	urine	20-55% as unchanged drug within 72 hours
	terminal half life	27 hours
	clearance	180 mL/min
Gender	no information found	
Elderly	no information found	
Children	no information found <sup>4</sup>	
Ethnicity	no information found	

Adapted from reference<sup>6</sup> unless specified otherwise

**USES:****Primary uses:**\*Tumour-induced hypercalcemia<sup>7-9</sup>\*Osteolytic bone metastases<sup>11-15</sup>

\*Health Canada approved indication

**Other uses:**Bone loss due to androgen suppression in prostate cancer<sup>10</sup>**SPECIAL PRECAUTIONS:****Contraindicated** in patients who have a history of hypersensitivity reaction to pamidronate or other bisphosphonates.<sup>4,6</sup>**Hydration:** In the treatment of acute tumour-induced hypercalcemia, patients must be adequately hydrated with intravenous NS (0.9% NaCl) before and during pamidronate therapy to expand intracellular volume and to increase renal calcium clearance.<sup>7,9</sup> The optimum infusion rate of NS should be determined by the severity of hypercalcemia, the degree of dehydration and the ability of the patient to tolerate fluid. Infusion rate of 200-300 mL/h has been commonly used. However, these infusion rates may require adjustment if signs and symptoms of fluid overload occur.<sup>9</sup>**Carcinogenicity:** Studies on rats and mice did not find pamidronate to have carcinogenic potential.<sup>6</sup>**Mutagenicity:** Pamidronate was not mutagenic in Ames test, mammalian *in vitro* mutation test or mammalian *in vivo* chromosome test.<sup>6</sup>**Fertility:** No information found.<sup>4</sup>**Pregnancy:** FDA Pregnancy Category C.<sup>4</sup> Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal, or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the fetus.**Breastfeeding** is not recommended due to the potential secretion into breast milk.<sup>6</sup>**SIDE EFFECTS:**

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important (reference expert reviewer). When placebo-controlled trials are available, adverse events are included if the incidence is  $\geq 5\%$  higher in the treatment group.

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b><i>bold, italics</i></b>	
blood/bone marrow/ febrile neutropenia	anemia* (35%)
	granulocytopenia* (17%)
	lymphocytopenia (1-10%)
	thrombocytopenia* (11%)
constitutional symptoms	asthenia* (16%)
	fatigue* (30%)

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b><i>bold, italics</i></b>	
	fever (36%)
dermatology/skin	<i>extravasation hazard</i> : none
	injection site reaction (2%)
gastrointestinal	<i>emetogenic potential</i> : nonemetogenic
	anorexia* (21%)
	constipation* (28%)
	diarrhea* (24%)
	dyspepsia* (14%)
	nausea* (48%)
	vomiting* (31%)
infection	upper respiratory infection* (20%)
	urinary tract infection* (15%)
metabolic/laboratory	hypocalcemia (3%)
	hypomagnesemia (1-10%)
	hypophosphatemia (>10%)
musculoskeletal	osteonecrosis of the jaw (rare) <sup>16-18</sup>
neurology	insomnia* (18%)
ocular/visual	conjunctivitis (rare) <sup>15</sup>
	uveitis (rare) <sup>15</sup>
pain	abdominal pain* (17%)
	headache* (24%)
	myalgia (23%)
	skeletal pain (59%)
pulmonary	cough* (21%)
	dyspnea* (23%)
syndromes	flu-like symptoms (>10%)

Adapted from reference<sup>6</sup> unless otherwise specified.

\*The incidences of these side effects are comparable to those of placebo group.

***Fever:*** Is a transient febrile reaction with > 1°C elevation in body temperature and may last up to 48 hours.<sup>6</sup> The fever usually occurs within 5 days of the first infusion of pamidronate and it may be accompanied by myalgia, nausea and headache.<sup>3</sup> It is usually self-limiting and does not require treatment.<sup>6</sup> If treatment is needed, acetaminophen may be used. Reducing the infusion rate is usually not helpful.<sup>3</sup>

***Hypocalcemia:*** Symptomatic hypocalcemia is rare<sup>3</sup> and the symptoms include abdominal cramps, confusion, muscle spasms, lethargy and irritability.<sup>4,19</sup> Patients who have undergone thyroid surgery may be more prone to develop hypocalcemia after pamidronate therapy and should be monitored closely.<sup>6,19</sup> Symptomatic hypocalcemia can be treated with oral or intravenous calcium supplement.<sup>6,19</sup>

**Osteonecrosis of the jaw (ONJ)** has been reported.<sup>16-18</sup> Refer to [Bisphosphonates and Osteonecrosis of the Jaw](#) in the Oral/Dental Care section of the Cancer Management Guidelines for more detailed information.

#### INTERACTIONS:

AGENT	EFFECT	MECHANISM	MANAGEMENT
calcium- or vitamin D-containing preparations <sup>4</sup>	may antagonize the effect of pamidronate in the treatment of hypercalcemia	additive	avoid concurrent therapy

#### SOLUTION PREPARATION AND COMPATIBILITY:

*For basic information on solution preparation and compatibility, see Chemotherapy Chart in Appendix.*

**Injection:** 30 mg, 60 mg and 90 mg vials; (as anhydrous pamidronate disodium); Preservative-free.<sup>6</sup> Store at room temperature.<sup>4</sup>

**Reconstitute** each 30 mg, 60 mg and 90 mg vial with 10 mL of SWI to yield pamidronate concentrations of 3 mg/mL, 6 mg/mL and 9 mg/mL, respectively. Reconstituted solution is stable for 24 hours at room temperature.<sup>6</sup>

**Diluted solution for infusion:** Must be further diluted with NS or D5W to concentrations less than or equal to 0.36 mg/mL. Diluted solution should be used within 24 hours from the initial reconstitution when stored at room temperature.<sup>6</sup>

**Compatibility:** It is recommended that pamidronate not be mixed with calcium-containing infusion solutions, such as Ringer's solution.<sup>6</sup>

#### PARENTERAL ADMINISTRATION:

BCCA administration standard noted in **bold, italics**

Subcutaneous	no information found
Intramuscular	no information found
Direct intravenous	not recommended since local reaction and thrombophlebitis may result from high local concentrations <sup>6</sup>
<b><i>Intermittent infusion</i></b>	<b><i>in 250 mL NS over 1 hour</i></b> <sup>20-22</sup> can also be given over 2-4 hours <sup>6,11,12</sup>
Continuous infusion	over 24 hours <sup>4,23</sup>
Intraperitoneal	no information found
Intrapleural	no information found
Intrathecal	no information found
Intra-arterial	no information found
Intravesical	no information found

**DOSAGE GUIDELINES:**

Refer to protocol by which patient is being treated.

**Adults:**

		BCCA usual dose noted in <b><i>bold, italics</i></b>
	Cycle Length:	
<i>Intravenous:</i>	<b>3-6 weeks<sup>6,11,12,24</sup></b>	<b><i>90 mg IV for one dose on day 1</i></b>
<i>for bone loss</i>	<b>12 weeks<sup>10</sup></b>	<b><i>60 mg IV for one dose on day 1</i></b>
<i>for hypercalcemia of malignancy</i>	<a href="#">Refer to BCCA Protocol Summary Guidelines for the Diagnosis and Management of Malignancy Related Hypercalcemia (BCCA Protocol SCHYPICAL) at <u>Supportive Care : BC Cancer Agency.</u></a>	

*Dosage in renal failure:* No adjustment is required when the recommended dose schedule is used. However, a maximum infusion rate of 22.5 mg/h is recommended in patients with renal dysfunction.<sup>6,25</sup> Moreover, there is limited experience with pamidronate in patients with serum creatinine > 440 µmol/L and caution should be used.<sup>6</sup>

*Dosage in hepatic failure:* no adjustment required<sup>6</sup>

*Dosage in dialysis* no information found

**Children:**

*intravenous:* 1-2 mg/kg IV over 3-24 hours has been used for tumour-induced hypercalcemia<sup>26</sup>

**REFERENCES:**

1. Lipton A. AREDIA® : the once-monthly infusion for the treatment of bone metastases. *Curr Opin Oncol* 1998;10(Suppl 1):S1-5.
2. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. *Drugs* 1991;42(6):919-944.
3. Coukell AJ, Markham A. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. *Drugs Aging* 1998;12(2):149-168.
4. USP DI. Volume I. Drug information for the health care professional. Pamidronate. 20th ed. Englewood, Colorado: Micromedex, Inc.; 2000. p. 2368-2370.
5. Brincker H, Westin J, Abildgaard N, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. *Br J Haematol* 1998;101(2):280-286.
6. Novartis Pharmaceuticals Canada Inc. AREDIA® product monograph. Laval, Quebec; 30 July 1999.
7. Purohit OP, Radstone CR, Anthony C, et al. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. *Br J Cancer* 1995;72(5):1289-1293.
8. Watters J, Gerrand G, Dodwell D. The management of malignant hypercalcaemia. *Drugs* 1996;52(6):837-848.
9. Chisholm MA, Mulloy AL, Taylor AT. Acute management of cancer-related hypercalcemia. *Ann Pharmacother* 1996;30(5):507-513.
10. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. *N Engl J Med* 2001;345(13):948-955.
11. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma AREDIA® Study Group [see comments]. *J Clin Oncol* 1998;16(2):593-602.
12. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Are dia Breast Cancer Study Group. *J Clin Oncol* 1998;16(6):2038-2044.
13. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 AREDIA® Breast Cancer Study Group. *J Clin Oncol* 1999;17(3):846-854.

14. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. *Cancer* 2000;88(5):1082-1090.
15. Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review [see comments]. *J Clin Oncol* 1998;16(3):1218-1225.
16. Marx RE. Pamidronate (AREDIA®) and zoledronate (ZOMETA®) induced avascular necrosis of the jaws: a growing epidemic. *J Oral Maxillofac Surg* 2003;61(9):1115-1117.
17. Carter GD, Goss AN. Bisphosphonates and avascular necrosis of the jaws. *Aust Dent J* 2003;48(4):268.
18. Novartis Pharmaceuticals Corporation. Updated safety: possible relationship of AREDIA® (pamidronate sodium) and/or ZOMETA® (zoledronic acid) with osteonecrosis of the jaw. 5 November 2004.
19. Sims EC, Rogers PB, Besser GM, et al. Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia. *Clin Oncol (Royal College Radiologists)* 1998;10(6):407-409.
20. Vilimovskij A, Thuerlimann B, Berenson JR, et al. Renal safety and tolerability of 90mg of aredia (pamidronate) administered as an intravenous 1 hour infusion: preliminary results. *Proc Am Soc Clin Oncol* 1999;18:576a (abstract 2223).
21. Tyrrell CJ, Collinson M, Madsen EL, et al. Intravenous pamidronate: infusion rate and safety. *Ann Oncol* 1994;5(Suppl 7):S27-29.
22. Tyrrell CJ. Role of pamidronate in the management of bone metastases from breast cancer: results of a non-comparative multicenter phase II trial. AREDIA® Multinational Cooperative Group. *Ann Oncol* 1994;5(Suppl 7):S37-40.
23. Machado CE, Flombaum CD. Safety of pamidronate in patients with renal failure and hypercalcemia. *Clin Nephrol* 1996;45(3):175-179.
24. BC Cancer Agency Multiple Myeloma Tumour Group. (MYPAM) BCCA protocol summary for treatment of multiple myeloma with pamidronate. Vancouver, British Columbia: BC Cancer Agency; 11 December 2000.
25. Berenson JR, Rosen L, Vescio R, et al. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. *J Clin Pharmacol* 1997;37(4):285-290.
26. Young G, Shende A. Use of pamidronate in the management of acute cancer-related hypercalcemia in children [see comments]. *Med Pediatr Oncol* 1998;30(2):117-121.